{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T04:00:33Z","timestamp":1792036833717,"version":"4.4.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2019,3,4]],"date-time":"2019-03-04T00:00:00Z","timestamp":1551657600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1007\/s12185-019-02620-2","type":"journal-article","created":{"date-parts":[[2019,3,4]],"date-time":"2019-03-04T03:13:02Z","timestamp":1551669182000},"page":"545-552","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Incidence of second malignancies in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitors"],"prefix":"10.1007","volume":"109","author":[{"given":"Koji","family":"Sasaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hagop M.","family":"Kantarjian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"O\u2019Brien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farhad","family":"Ravandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Konopleva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gautam","family":"Borthakur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo","family":"Garcia-Manero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William G.","family":"Wierda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naval","family":"Daver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Ferrajoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Preetesh","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Beth","family":"Rios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherry A.","family":"Pierce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elias J.","family":"Jabbour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge E.","family":"Cortes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,3,4]]},"reference":[{"issue":"3","key":"2620_CR1","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1200\/JCO.2017.74.7162","volume":"36","author":"JE Cortes","year":"2018","unstructured":"Cortes JE, Gambacorti-Passerini C, Deininger MW, Mauro MJ, Chuah C, Kim DW, et al. Bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia: results from the randomized BFORE trial. J Clin Oncol. 2018;36(3):231\u20137.","journal-title":"J Clin Oncol"},{"issue":"19","key":"2620_CR2","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1056\/NEJMoa1306494","volume":"369","author":"JE Cortes","year":"2013","unstructured":"Cortes JE, Kim DW, Pinilla-Ibarz J, le Coutre P, Paquette R, Chuah C, et al. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med. 2013;369(19):1783\u201396.","journal-title":"N Engl J Med"},{"issue":"20","key":"2620_CR3","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1200\/JCO.2015.64.8899","volume":"34","author":"JE Cortes","year":"2016","unstructured":"Cortes JE, Saglio G, Kantarjian HM, Baccarani M, Mayer J, Boque C, et al. Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-naive chronic myeloid leukemia patients trial. J Clin Oncol. 2016;34(20):2333\u201340.","journal-title":"J Clin Oncol"},{"issue":"10","key":"2620_CR4","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1056\/NEJMoa1609324","volume":"376","author":"A Hochhaus","year":"2017","unstructured":"Hochhaus A, Larson RA, Guilhot F, Radich JP, Branford S, Hughes TP, et al. Long-term outcomes of imatinib treatment for chronic myeloid leukemia. N Engl J Med. 2017;376(10):917\u201327.","journal-title":"N Engl J Med"},{"issue":"5","key":"2620_CR5","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1038\/leu.2016.5","volume":"30","author":"A Hochhaus","year":"2016","unstructured":"Hochhaus A, Saglio G, Hughes TP, Larson RA, Kim DW, Issaragrisil S, et al. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia. 2016;30(5):1044\u201354.","journal-title":"Leukemia"},{"issue":"3","key":"2620_CR6","doi-asserted-by":"publisher","first-page":"e118-28","DOI":"10.1016\/S2352-3026(15)00021-6","volume":"2","author":"P Jain","year":"2015","unstructured":"Jain P, Kantarjian H, Alattar ML, Jabbour E, Sasaki K, Nogueras Gonzalez G, et al. Long-term molecular and cytogenetic response and survival outcomes with imatinib 400 mg, imatinib 800 mg, dasatinib, and nilotinib in patients with chronic-phase chronic myeloid leukaemia: retrospective analysis of patient data from five clinical trials. Lancet Haematol. 2015;2(3):e118-28.","journal-title":"Lancet Haematol"},{"issue":"6","key":"2620_CR7","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1182\/blood-2006-02-004325","volume":"108","author":"HM Kantarjian","year":"2006","unstructured":"Kantarjian HM, Talpaz M, O\u2019Brien S, Jones D, Giles F, Garcia-Manero G, et al. Survival benefit with imatinib mesylate versus interferon-alpha-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia. Blood. 2006;108(6):1835\u201340.","journal-title":"Blood"},{"issue":"5","key":"2620_CR8","doi-asserted-by":"publisher","first-page":"e186-93","DOI":"10.1016\/S2352-3026(15)00048-4","volume":"2","author":"K Sasaki","year":"2015","unstructured":"Sasaki K, Strom SS, O\u2019Brien S, Jabbour E, Ravandi F, Konopleva M, et al. Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials. Lancet Haematol. 2015;2(5):e186-93.","journal-title":"Lancet Haematol"},{"issue":"6","key":"2620_CR9","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1038\/leu.2016.20","volume":"30","author":"MB Miranda","year":"2016","unstructured":"Miranda MB, Lauseker M, Kraus MP, Proetel U, Hanfstein B, Fabarius A, et al. Secondary malignancies in chronic myeloid leukemia patients after imatinib-based treatment: long-term observation in CML Study IV. Leukemia. 2016;30(6):1255\u201362.","journal-title":"Leukemia"},{"issue":"5","key":"2620_CR10","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1111\/bjh.13346","volume":"169","author":"N Gunnarsson","year":"2015","unstructured":"Gunnarsson N, Stenke L, Hoglund M, Sandin F, Bjorkholm M, Dreimane A, et al. Second malignancies following treatment of chronic myeloid leukaemia in the tyrosine kinase inhibitor era. Br J Haematol. 2015;169(5):683\u20138.","journal-title":"Br J Haematol"},{"issue":"16","key":"2620_CR11","doi-asserted-by":"publisher","first-page":"4353","DOI":"10.1182\/blood-2011-06-362889","volume":"118","author":"D Verma","year":"2011","unstructured":"Verma D, Kantarjian H, Strom SS, Rios MB, Jabbour E, Quintas-Cardama A, et al. Malignancies occurring during therapy with tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia (CML) and other hematologic malignancies. Blood. 2011;118(16):4353\u20138.","journal-title":"Blood"},{"issue":"4","key":"2620_CR12","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1007\/s12288-013-0328-2","volume":"30","author":"BK Shah","year":"2014","unstructured":"Shah BK, Ghimire KB. Second primary malignancies in chronic myeloid leukemia. Indian J Hematol Blood Transfus. 2014;30(4):236\u201340.","journal-title":"Indian J Hematol Blood Transfus"},{"issue":"5 Suppl","key":"2620_CR13","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1002\/cncr.22013","volume":"107","author":"F Ahmed","year":"2006","unstructured":"Ahmed F, Goodman MT, Kosary C, Ruiz B, Wu XC, Chen VW, et al. Excess risk of subsequent primary cancers among colorectal carcinoma survivors, 1975\u20132001. Cancer. 2006;107(5 Suppl):1162\u201371.","journal-title":"Cancer"},{"key":"2620_CR14","unstructured":"National Cancer Institute: Surveillance E, and End results Program. Cancer Stat facts: leukemia\u2014chronic myeloid leukemia (CML). 2018. \n                    https:\/\/seer.cancer.gov\/statfacts\/html\/cmyl.html\n                    \n                  ."},{"issue":"2","key":"2620_CR15","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1002\/cncr.29745","volume":"122","author":"K Sasaki","year":"2016","unstructured":"Sasaki K, Kantarjian HM, Jain P, Jabbour EJ, Ravandi F, Konopleva M, et al. Conditional survival in patients with chronic myeloid leukemia in chronic phase in the era of tyrosine kinase inhibitors. Cancer. 2016;122(2):238\u201348.","journal-title":"Cancer"},{"issue":"3","key":"2620_CR16","doi-asserted-by":"publisher","first-page":"161","DOI":"10.7326\/M15-2306","volume":"165","author":"T Dahlen","year":"2016","unstructured":"Dahlen T, Edgren G, Lambe M, Hoglund M, Bjorkholm M, Sandin F, et al. Cardiovascular events associated with use of tyrosine kinase inhibitors in chronic myeloid leukemia: a population-based cohort study. Ann Intern Med. 2016;165(3):161\u20136.","journal-title":"Ann Intern Med"},{"issue":"5","key":"2620_CR17","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1001\/jamaoncol.2015.5932","volume":"2","author":"J Douxfils","year":"2016","unstructured":"Douxfils J, Haguet H, Mullier F, Chatelain C, Graux C, Dogne JM. Association between BCR-ABL tyrosine kinase inhibitors for chronic myeloid leukemia and cardiovascular events, major molecular response, and overall survival: a systematic review and meta-analysis. JAMA Oncol. 2016;2(5):625\u201332.","journal-title":"JAMA Oncol"},{"issue":"1","key":"2620_CR18","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21442","volume":"68","author":"RL Siegel","year":"2018","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7\u201330.","journal-title":"CA Cancer J Clin"},{"key":"2620_CR19","doi-asserted-by":"publisher","first-page":"e4342","DOI":"10.7717\/peerj.4342","volume":"6","author":"V Kumar","year":"2018","unstructured":"Kumar V, Garg M, Chaudhary N, Chandra AB. An observational study on risk of secondary cancers in chronic myeloid leukemia patients in the TKI era in the United States. PeerJ. 2018;6:e4342.","journal-title":"PeerJ"},{"issue":"7","key":"2620_CR20","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s12032-018-1159-7","volume":"35","author":"T Nakazato","year":"2018","unstructured":"Nakazato T, Iriyama N, Tokuhira M, Ishikawa M, Sato E, Takaku T, et al. Incidence and outcome of second malignancies in patients with chronic myeloid leukemia during treatment with tyrosine kinase inhibitors. Med Oncol. 2018;35(7):99.","journal-title":"Med Oncol"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-019-02620-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12185-019-02620-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-019-02620-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,2]],"date-time":"2020-03-02T19:24:10Z","timestamp":1583177050000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12185-019-02620-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,4]]},"references-count":20,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["2620"],"URL":"https:\/\/doi.org\/10.1007\/s12185-019-02620-2","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,4]]},"assertion":[{"value":"31 January 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"HMK received research grants from Novartis, Bristol-Myers Squibb, Pfizer, and Ariad. FR received research funding from Novartis and Bristol-Myers Squibb. EJJ received consultancy fees from Ariad, Bristol-Myers Squibb, Teva, and Pfizer. JEC received research support from Ariad, Bristol-Myers Squibb, Novartis, Pfizer, and Teva and is a consultant for Ariad, Bristol-Myers Squibb, Novartis, and Pfizer. KS, SO\u2019B, MK, GB, GGM, WGW, ND, AF, KT, PJ, MBR, and SAP declare that they have no relevant conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}